TNFRSF8 and T-cell non-Hodgkin lymphoma: Finally, the constructed MU-CAR-T cells were successfully validated for their therapeutic effects in anti-infection and anti-tumor utilizing both in vitro and in vivo experiments, which was represented by VRC01 scFv-mediated efficient killing of latent HIV-1-infected cells and CD5-CD30 scFvs-mediated successful suppression of T cell lymphoma.